08Jun
FDA Signals a Deliberative Approach to Cannabis at Public Hearing
While it was ostensibly convened to gather scientific input from stakeholders on how to appropriately regulate cannabis-infused products, the Food and Drug Administration (FDA) also used the May 31, 2019 public hearing as a platform to issue a call...
By:
Wilson Sonsini Goodrich & Rosati
Related
The recent rejection of an attempt to dismiss emotional distress claims offers a prescient reminder ...
Read More >
Compliance into the Weeds is the only weekly podcast which takes a deep dive into a compliance relat...
Read More >
Whistleblowing can and should be an essential tool for organisations who want to deliver effective c...
Read More >
A private equity (PE) transaction can help physicians “hedge” the uncertain future of private medi...
Read More >
Alex Acosta’s resignation from the Labor Secretary post signaled a quick blow to a key member of Pr...
Read More >
With the situation surrounding the 2019 Novel Coronavirus (COVID-19) rapidly changing, multinational...
Read More >